Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests

Infection Control and Hospital Epidemiology

Volumn 33, Issue 8, 2012, Pages 853-855

  Marchaim, Dror ^a   Sunkara, Bharath ^a   Lephart, Paul R ^a   Gudur, Uma Mahesh ^a   Bhargava, Ashish ^a   Mynatt, Ryan P ^a   Zhao, Jing J ^a   Bheemreddy, Suchitha ^a   Hayakawa, Kayoko ^a   Chopra, Teena ^a   Dhar, Sorabh ^a   Kaye, Keith S ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFEPIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; EXTENDED SPECTRUM BETA LACTAMASE; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BROTH DILUTION; ESCHERICHIA COLI; HUMAN; INOCULATION; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEFUROXIME; CEPHALOSPORINS; ESCHERICHIA COLI; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN;

EID: 84863730126     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/666632     Document Type: Article

References (11)

1. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and metaanalysis. J Antimicrob Chemother 2007;60(5):913-920.
2. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement. Approved standard M100-S19. Wayne, PA: CLSI, 2009.
3. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin Infect Dis 2004; 39(1):31-37.
4. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005;18(4):657-686.
5. Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012;54(2):167-174.
6. Clinical and Laboratory Standards Institute (CLSI). CLSIM100-S20 (2010) Cephalosporin and Aztreonam Breakpoint Revisions Fact Sheet. Wayne, PA: CLSI, 2010.
7. Jenkins SG. Rationale Supporting CLSI Changes to Interpretive Criteria (Breakpoints) for Several Cephalosporines and Aztreonam When Testing Enterobacteriaceae. Washington, DC: American Society for Microbiology, 2010:1-4.
8. Rodriguez-Bano J, Picon E, Navarro MD, Lopez-Cerero L, Pascual A. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli. Clin Microbiol Infect doi:10.1111/j.1469-0691.2011.03673.x. Published September 13, 2011.
9. de Oliveira KR, de Freitas AL, Willers DM, Barth AL, Zavascki AP. High frequency of β-lactam susceptibility in CTX-M-type extended-spectrum-β-lactamase-producing Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis according to the new CLSI recommendations. J Antimicrob Chemother 2010;65(11): 2481-2483.
10. Ambrose PG, Bhavnani SM, Jones RN. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases: report from the ARREST program. Antimicrob Agents Chemother 2003;47(5): 1643-1646.
11. Perez F, Bonomo RA. Can we really use β-lactam/β-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum β-lactamase-producing bacteria? Clin Infect Dis 2012;54(2):175-177.